But, getting to "biotech-researchers" post, do you really think it's likely of BMY or NVS spending a couple of billion (or more) on ARIA because they're afraid of ARIA running a front-line trial?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.